EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease

Barbara Miziak, Ryszard Pluta iD, Stanisław J Czuczwar

International Journal of Molecular Sciences · 06.11.2026 · 27 (21) · 9959

DOI: 10.3390/ijms27219959 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.11.2026. Verfasst von Barbara Miziak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit nennt 138 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Lublin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD), as a chronic neurodegenerative disorder, leads to progressive dementia. About 60–80% of dementia cases are due to AD, and their incidence increases especially after the age of 65. AD is characterized by impaired memory, abnormal behavior, and impaired thinking process, which causes limitation of daily activities and a gradual loss of independence. The costs of all dementia cases are likely to reach $2 trillion in 2030 alone. Currently available pharmacological treatment of AD is, for the most part, not causal, and does not modify the course of the disease. The data search for procognitive drugs was carried out using the PUBMED and Clinical Science databases. Among the drugs with animal data and preliminary clinical trials, the following can be distinguished: fosgonimeton, blarcamesine, bezisterim, posiphen (buntanetap) and ACD856. As a rule, promising preclinical results were not confirmed in clinical trials. Some clinical expectations may be associated with posiphen and ACD856. Based on preclinical data, the following drugs seem promising: tenuigenin, JQ1, gemfibrozil, coumarin derivatives, ponicidin, salicin, calcaratarin D, new 1,3,5-triazines or 2-aminopyrymidine carboxamide derivatives, epimedium brevicornu flavonoids, and drugs affecting the glymphatic system. In general, the above-mentioned drugs counteract the pathologies leading to the occurrence of AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAnimals

Stichwörter der Autor:innen

ACD856Alzheimer’s diseaseanti-tau protein monoclonal antibodiesbezisterimcoumarin derivativesgemfibrozilponicidinposiphensalicintenuigenin

Autor:innen und Institutionen

  • Department of Pathophysiology, Medical University of Lublin, 20-090 Lublin, Poland.

ORCID-Profile: Ryszard Pluta

Förderung

  • Medical University of Lublin

Zitieren

APA

Miziak, B., Pluta, R., & Czuczwar, S. J. (2026). Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease. International Journal of Molecular Sciences, 27(21), 9959. https://doi.org/10.3390/ijms27219959

Vancouver

Miziak B, Pluta R, Czuczwar SJ. Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease. International Journal of Molecular Sciences. 2026;27(21):9959. doi:10.3390/ijms27219959

BibTeX
@article{Miziak2026,
  author = {Miziak, Barbara and Pluta, Ryszard and Czuczwar, Stanisław J},
  title = {Current Possible Newer Pharmacological Treatment Options for Alzheimer’s Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {21},
  pages = {9959},
  doi = {10.3390/ijms27219959}
}
Kostenlos starten →